Latest Health Technology at CES 2021
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
Ligelizumab is a high-affinity monoclonal anti-immunoglobulin E (IgE) antibody.
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Orladeyo works by binding to plasma kallikrein and inhibiting its proteolytic activity.
An exhalation delivery system appears to more effectively apply topical steroids to nasal polyps located in the ostiomeatal complex.
The safety and efficacy of crisaborole ointment, 2%, was examined in pediatric patients with mild to moderate atopic dermatitis with and without comorbid allergic rhinitis.
Larger skin flare results in pediatric patients correlated to failing certain oral food challenges, but were not predictive of requiring epinephrine.
Treatment with omalizumab for up to 1 year was associated with continued improvements in symptoms of chronic rhinosinusitis with nasal polyps.
Lanadelumab was effective for reducing hereditary angioedema attacks at up to 30 weeks of treatment, suggesting the monoclonal antibody is associated with sustained long-term efficacy.
Patients with hereditary angioedema taking berotralstat prophylactically had improved quality of life.